May 23, 2019: How CD4 variables over time affect anal cancer risk; when to consider anal pap smears for women; switching from E/C/F/TAF to ABC/3TC; new data on marijuana use among people with HIV.
Experts push for normalization of PrEP; U.S. HIV transmission rates across the care continuum; sociodemographic disadvantage and HIV drug resistance; real-world success of integrase inhibitors for treatment-experienced people.
In clinical trials called Sword 1 and Sword 2, researchers testing a combination of dolutegravir/rilpivirine (Juluca) found it to be effective and tolerable.
What are the benefits and risks of marijuana use for people living with HIV? The answer is complicated, and explains why clinician-patient communication on the issue is increasingly important.
Delstrigo, a fixed-dose combination regimen containing the newly approved antiretroviral doravirine (Pifeltro), lamivudine (3TC, Epivir), and tenofovir disoproxil fumarate (Viread), was non-inferior to other triple combination therapies in participan...
Poor rates of cervical cancer screening for women of color; interest vs. action among potential organ donors; an online depression intervention; Truvada levels in men’s vs. women’s hair.
Drug-drug interactions and side effects, associated with currently-used first-line antiretroviral therapy, are under-reported and managed in Uganda.
On June 6, 2018, without news from the U.S. FDA, a press release from Frontier Biotech announced the approval of a new HIV drug in China that is given by once-weekly injection.
Happy days for thrice-weekly dosing; shortfalls in chronic opioid therapy monitoring; neurocognition, treatment initiation, and high CD4; the link between influenza virus shedding and CD4 count.
The detection, diagnosis, and treatment of HIV has evolved rapidly. This review summarizes the past, present, and future of antiretrovirals for the treatment and prevention of HIV.